8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Apr 28, 2026·SEC
Material company update
Feb 19, 2026·SEC
Madrigal Pharmaceuticals, Inc.(MDGL)Earnings, Financials & Key Ratios
MDGL•NASDAQ
Price updated Jun 19, 2026
AboutMadrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.Show more
- Revenue$958M+432.1%
- EBITDA-$299M+39.9%
- Net Income-$288M+38.1%
- EPS (Diluted)-12.85+41.3%
- Gross Margin94.14%-2.5%
- EBITDA Margin-31.16%+88.7%
- Operating Margin-31.31%+88.7%
- Net Margin-30.08%+88.4%
- ROE-42.49%+47.1%
MDGL Key Insights
Madrigal Pharmaceuticals, Inc. (MDGL) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Expensive at 18.8x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when MDGL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MDGL Price & Volume
Madrigal Pharmaceuticals, Inc. (MDGL) stock price & volume — 10-year historical chart
Loading chart...
MDGL Growth Metrics
Madrigal Pharmaceuticals, Inc. (MDGL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM256.82%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM20.98%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM29.09%
Return on Capital
10 Years-66.26%
5 Years-89.36%
3 Years-67.77%
Last Year-32.94%
MDGL Recent Earnings
Madrigal Pharmaceuticals, Inc. (MDGL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 5/12 qtrs (63%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$3.25+10.0%
$3.61
Rev
$311M+3.4%
$301M
Q1 2026
Feb 19, 2026Metric
Actual
Est
EPS
$2.57-6525.0%
$0.04
Rev
$321M+2.8%
$313M
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$5.08-149.4%
$2.04
Rev
$287M+17.3%
$245M
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$1.90+45.4%
$3.48
Rev
$213M-12.6%
$243M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $3.25vs $3.61+10.0% | $311Mvs $301M+3.4% |
| Q1 2026 | Feb 19, 2026 | $2.57vs $0.04-6525.0% | $321Mvs $313M+2.8% |
| Q4 2025 | Nov 4, 2025 | $5.08vs $2.04-149.4% | $287Mvs $245M+17.3% |
| Q3 2025 | Aug 5, 2025 | $1.90vs $3.48+45.4% | $213Mvs $243M-12.6% |
Based on last 12 quarters of dataView full earnings history →
MDGL Peer Comparison
Madrigal Pharmaceuticals, Inc. (MDGL) competitors in Metabolic and Obesity Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 AKRO | 4.5B | 54.65 | -14.57 | -30.58% | 0.05 | |||
 HIMS | 7.79B | 35.47 | 69.55 | 59% | -0.56% | -2.48% | 2.34 | |
 ELVN | 2.75B | 45.10 | -24.64 | -21.04% | 0.00 | |||
 TERN | 4.77B | 52.95 | -51.41 | -20.02% | 0.00 | |||
 GPCR | 2.56B | 44.51 | -18.55 | -15.14% | 0.00 | |||
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 | |
 ARWR | 11.52B | 81.82 | -6706.56 | 232.58% | -48.38% | -55.09% | 0.73 |
Compare MDGL vs Peers
Madrigal Pharmaceuticals, Inc. (MDGL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MDGL Income Statement
Madrigal Pharmaceuticals, Inc. (MDGL) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 180.13M | 958.4M | 1.13B |
Revenue Growth % | - | - | - | - | - | - | - | - | 432.05% | 256.82% |
Cost of Goods Sold | 77K | 96K | 112K | 471K | 0 | 0 | 0 | 6.23M | 56.15M | 78.48M |
COGS % of Revenue | - | - | - | - | - | - | - | 3.46% | 5.86% | - |
Gross Profit | -77K▲ 0% | -96K▼ 24.7% | -112K▼ 16.7% | -471K▼ 320.5% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 173.9M▲ 0% | 902.25M▲ 418.8% | 1.05B▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | 96.54% | 94.14% | 93.07% |
Gross Profit Growth % | -49258.97% | -24.68% | -16.67% | -320.54% | 100% | - | - | - | 418.84% | - |
Operating Expenses | 31.81M | 40.36M | 94.86M | 205.85M | 242.48M | 293.57M | 380.5M | 671.77M | 1.2B | 1.37B |
OpEx % of Revenue | - | - | - | - | - | - | - | 372.93% | 125.45% | - |
Selling, General & Admin | 7.67M | 14.97M | 22.65M | 21.86M | 37.32M | 48.13M | 108.15M | 435.06M | 813.83M | 914.47M |
SG&A % of Revenue | - | - | - | - | - | - | - | 241.52% | 84.91% | - |
Research & Development | 24.39M | 25.39M | 72.32M | 184.81M | 205.16M | 245.44M | 272.35M | 236.72M | 388.52M | 453.05M |
R&D % of Revenue | - | - | - | - | - | - | - | 131.41% | 40.54% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -31.89M▲ 0% | -40.46M▼ 26.9% | -94.97M▼ 134.8% | -206.32M▼ 117.2% | -242.48M▼ 17.5% | -293.57M▼ 21.1% | -380.5M▼ 29.6% | -497.88M▼ 30.8% | -300.1M▲ 39.7% | -313.51M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | -276.39% | -31.31% | -27.68% |
Operating Income Growth % | -27.64% | -26.88% | -134.75% | -117.24% | -17.53% | -21.07% | -29.61% | -30.85% | 39.72% | - |
EBITDA | -31.81M | -40.36M | -94.86M | -205.85M | -242.08M | -293.1M | -379.97M | -496.78M | -298.59M | -312.38M |
EBITDA Margin % | - | - | - | - | - | - | - | -275.78% | -31.16% | -27.58% |
EBITDA Growth % | -27.33% | -26.88% | -135.03% | -117% | -17.6% | -21.08% | -29.64% | -30.74% | 39.89% | 26.3% |
D&A (Non-Cash Add-back) | 77K | 96K | 112K | 471K | 405K | 467K | 527K | 1.1M | 1.51M | 1.13M |
EBIT | -31.15M | -32.81M | -83.95M | -202.24M | -241.85M | -291.39M | -360.92M | -451.22M | -265.98M | -288.76M |
Net Interest Income | 558K | 7.67M | 11.02M | 4.33M | 363K | -1.78M | 6.87M | 31.98M | 15.05M | 8.98M |
Interest Income | 558K | 7.67M | 11.02M | 4.33M | 363K | 2.19M | 19.58M | 46.65M | 37.36M | 36.24M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 3.96M | 12.71M | 14.67M | 22.31M | 11.19M |
Other Income/Expense | 732K | 7.64M | 11.02M | 4.08M | 636K | -1.78M | 6.87M | 31.98M | 11.81M | 4.07M |
Pretax Income | -31.15M▲ 0% | -32.81M▼ 5.3% | -83.95M▼ 155.9% | -202.24M▼ 140.9% | -241.85M▼ 19.6% | -295.35M▼ 22.1% | -373.63M▼ 26.5% | -465.89M▼ 24.7% | -288.28M▲ 38.1% | -309.44M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | -258.64% | -30.08% | -27.32% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -31.15M▲ 0% | -32.81M▼ 5.3% | -83.95M▼ 155.9% | -202.24M▼ 140.9% | -241.85M▼ 19.6% | -295.35M▼ 22.1% | -373.63M▼ 26.5% | -465.89M▼ 24.7% | -288.28M▲ 38.1% | -309.44M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | -258.64% | -30.08% | -27.32% |
Net Income Growth % | -18.06% | -5.32% | -155.85% | -140.92% | -19.58% | -22.12% | -26.5% | -24.69% | 38.12% | 20.98% |
Net Income (Continuing) | -31.15M | -32.81M | -83.95M | -202.24M | -241.85M | -295.35M | -373.63M | -465.89M | -288.28M | -309.44M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -2.54▲ 0% | -2.22▲ 12.6% | -4.73▼ 113.1% | -13.09▼ 176.7% | -14.63▼ 11.8% | -17.23▼ 17.8% | -19.99▼ 16.0% | -21.90▼ 9.6% | -12.85▲ 41.3% | -10.66▲ 0% |
EPS Growth % | 49.9% | 12.6% | -113.06% | -176.74% | -11.76% | -17.77% | -16.02% | -9.55% | 41.32% | 29.09% |
EPS (Basic) | -2.54 | -2.22 | -4.73 | -13.09 | -14.63 | -17.23 | -19.99 | -21.90 | -12.85 | - |
Diluted Shares Outstanding | 12.24M | 14.8M | 15.39M | 15.45M | 16.54M | 17.14M | 18.69M | 21.27M | 22.43M | 29.03M |
Basic Shares Outstanding | 12.24M | 14.8M | 15.39M | 15.45M | 16.54M | 17.14M | 18.69M | 21.27M | 22.43M | 29.03M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
MDGL Balance Sheet
Madrigal Pharmaceuticals, Inc. (MDGL) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 192.01M | 485.2M | 440.2M | 285.16M | 271.68M | 361.37M | 637.28M | 1.03B | 1.25B | 1.18B |
Cash & Short-Term Investments | 191.53M | 483.72M | 439.05M | 284.15M | 270.35M | 358.77M | 634.13M | 926.25M | 983.56M | 817.93M |
Cash Only | 148.63M | 57.38M | 46.7M | 54M | 36.27M | 331.55M | 99.92M | 100.02M | 198.69M | 232.19M |
Short-Term Investments | 42.9M | 426.34M | 392.35M | 230.15M | 234.08M | 27.23M | 534.22M | 826.23M | 784.87M | 585.74M |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 53.82M | 134.48M | 187.36M |
Days Sales Outstanding | - | - | - | - | - | - | - | 109.06 | 51.21 | 41.44 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 34.07M | 74.84M | 112.07M |
Days Inventory Outstanding | - | - | - | - | - | - | - | 1.99K | 486.52 | 371.74 |
Other Current Assets | 485K | 1.48M | 1.15M | 0 | 0 | 2.6M | 3.15M | 18.79M | 52.89M | 64.95M |
Total Non-Current Assets | 301K | 227K | 1.86M | 1.83M | 1.65M | 1.2M | 3.27M | 9.32M | 13.82M | 45.02M |
Property, Plant & Equipment | 301K | 227K | 1.86M | 1.83M | 1.65M | 1.2M | 3.27M | 4.59M | 6.44M | 14.24M |
Fixed Asset Turnover | - | - | - | - | - | - | - | 39.24x | 148.87x | 124.27x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.73M | 7.38M | 7.28M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 23.5M |
Total Assets | 192.31M▲ 0% | 485.43M▲ 152.4% | 442.06M▼ 8.9% | 287M▼ 35.1% | 273.33M▼ 4.8% | 362.57M▲ 32.6% | 640.55M▲ 76.7% | 1.04B▲ 62.7% | 1.26B▲ 20.9% | 1.23B▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | 0.17x | 0.76x | 0.93x |
Asset Growth % | 366.67% | 152.42% | -8.93% | -35.08% | -4.76% | 32.65% | 76.67% | 62.71% | 20.85% | 63.27% |
Total Current Liabilities | 10.05M | 8.44M | 25.13M | 46.56M | 76.84M | 115.89M | 118.55M | 169.28M | 310.29M | 338.26M |
Accounts Payable | 1.93M | 2.49M | 1.18M | 1.02M | 21.38M | 23.83M | 28.04M | 43.6M | 48.88M | 60.8M |
Days Payables Outstanding | 9.14K | 9.46K | 3.84K | 788.12 | - | - | - | 2.55K | 317.74 | 223.93 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.02M | 1.7M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 1.8M | 2.78M | 4.69M | 6.77M | 14.86M | 17.03M | 34.96M | 260.39M | 241.43M |
Current Ratio | 19.10x | 57.46x | 17.52x | 6.13x | 3.54x | 3.12x | 5.38x | 6.10x | 4.01x | 3.50x |
Quick Ratio | 19.10x | 57.46x | 17.52x | 6.13x | 3.54x | 3.12x | 5.38x | 5.90x | 3.77x | 3.16x |
Cash Conversion Cycle | - | - | - | - | - | - | - | -449.07 | 219.99 | 189.26 |
Total Non-Current Liabilities | 0 | 0 | 361K | 468K | 387K | 49.29M | 116.67M | 118.59M | 346.61M | 345.61M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 49.29M | 115.48M | 117.57M | 346.61M | 340.33M |
Capital Lease Obligations | 0 | 0 | 361K | 468K | 387K | 0 | 1.19M | 1.02M | 6.73M | 22.11M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -6.73M | 0 |
Total Liabilities | 10.05M | 8.44M | 25.49M | 47.02M | 77.22M | 165.18M | 235.21M | 287.86M | 656.9M | 683.87M |
Total Debt | 0 | 0 | 676K | 786K | 797K | 49.89M | 117.19M | 119.57M | 354.36M | 347.31M |
Net Debt | -191.53M | -483.72M | -46.02M | -53.22M | -35.47M | -281.66M | 17.28M | 19.55M | 155.67M | 115.12M |
Debt / Equity | - | - | 0.00x | 0.00x | 0.00x | 0.25x | 0.29x | 0.16x | 0.59x | 0.64x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -1.11x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.37x |
Interest Coverage | - | - | - | - | - | -73.51x | -28.39x | -30.76x | -11.92x | -25.80x |
Total Equity | 182.26M▲ 0% | 476.98M▲ 161.7% | 416.56M▼ 12.7% | 239.97M▼ 42.4% | 196.11M▼ 18.3% | 197.39M▲ 0.7% | 405.33M▲ 105.3% | 754.38M▲ 86.1% | 602.69M▼ 20.1% | 543.45M▲ 0% |
Equity Growth % | 400.57% | 161.71% | -12.67% | -42.39% | -18.28% | 0.65% | 105.35% | 86.11% | -20.11% | -81.92% |
Book Value per Share | 14.88 | 32.24 | 27.06 | 15.54 | 11.86 | 11.52 | 21.69 | 35.46 | 26.86 | 18.72 |
Total Shareholders' Equity | 182.26M | 476.98M | 416.56M | 239.97M | 196.11M | 197.39M | 405.33M | 754.38M | 602.69M | 543.45M |
Common Stock | 1K | 2K | 2K | 2K | 2K | 2K | 2K | 2K | 2K | 2K |
Retained Earnings | -106.46M | -139.27M | -223.22M | -425.46M | -667.31M | -962.66M | -1.34B | -1.8B | -2.09B | -2.18B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -31K | -319K | 216K | 47K | -80K | -32K | 468K | 468K | 873K | 1.08M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MDGL Cash Flow Statement
Madrigal Pharmaceuticals, Inc. (MDGL) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -22.32M | -25.51M | -41.62M | -157.56M | -183.92M | -224.86M | -324.23M | -455.57M | -189.55M | -268.1M |
Operating CF Margin % | - | - | - | - | - | - | - | -252.91% | -19.78% | - |
Operating CF Growth % | -26.75% | -14.29% | -63.19% | -278.53% | -16.73% | -22.26% | -44.19% | -40.51% | 58.39% | 168.25% |
Net Income | -31.15M | -32.81M | -83.95M | -202.24M | -241.85M | -295.35M | -373.63M | -465.89M | -288.28M | -309.44M |
Depreciation & Amortization | 77K | 96K | 112K | 471K | 405K | 467K | 527K | 696K | 4.72M | 3.39M |
Stock-Based Compensation | 3.25M | 13.49M | 22.76M | 20.73M | 26.87M | 31.63M | 49.73M | 79.88M | 98.13M | 85.43M |
Deferred Taxes | 0 | 0 | 0 | -21.83M | -7.32M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 2.49M | 13.12M | 0 | 21.83M | 7.32M | 797K | 2.41M | 2.09M | 4.38M | 29.43M |
Working Capital Changes | 5.51M | -6.28M | 19.45M | 23.48M | 30.65M | 37.6M | -3.28M | -72.34M | -8.5M | -76.91M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -53.82M | -80.65M | -125.93M |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -34.07M | -36.98M | -37.99M |
Change in Payables | 917K | 558K | -1.31M | -161K | 20.36M | 2.45M | 4.21M | 15.56M | 5.28M | 10.41M |
Cash from Investing | -22.01M | -380.08M | 30.71M | 159.78M | -5.05M | 206.69M | -502.52M | -274.39M | 32.32M | 60.63M |
Capital Expenditures | -125K | -22K | -172K | -334K | -209K | -217K | -1.48M | -1.46M | -467K | -7.32M |
CapEx % of Revenue | - | - | - | - | - | - | - | 0.81% | 0.05% | 0.65% |
Acquisitions | 0 | -3.67M | 0 | 1.92M | 787K | -3K | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -21.88K | 3.67M | 0 | -1.92M | -787K | 3K | 0 | 19.09M | -8.97M | 0 |
Cash from Financing | 173.81M | 314.33M | 235K | 5.09M | 171.24M | 313.45M | 595.12M | 735.06M | 255.98M | 249.67M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 50M | 65M | 0 | 217.93M | 217.93M |
Equity Issued (Net) | 173.81M | 311.82M | 0 | 4.42M | 170.21M | 255.38M | 260.19M | 397.49M | 38.05M | 21.36M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 2.51M | 235K | 667K | 1.03M | 8.07M | 269.93M | 337.57M | 0 | 10.38M |
Net Change in Cash | 129.48M▲ 0% | -91.25M▼ 170.5% | -10.68M▲ 88.3% | 7.31M▲ 168.4% | -17.73M▼ 342.7% | 295.28M▲ 1765.0% | -231.63M▼ 178.4% | 5.1M▲ 102.2% | 98.76M▲ 1835.0% | 43.54M▲ 0% |
Free Cash Flow | -22.44M▲ 0% | -25.53M▼ 13.8% | -41.8M▼ 63.7% | -157.9M▼ 277.8% | -184.13M▼ 16.6% | -225.07M▼ 22.2% | -325.71M▼ 44.7% | -457.03M▼ 40.3% | -190.02M▲ 58.4% | -272.41M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | -253.72% | -19.83% | -24.05% |
FCF Growth % | -27.43% | -13.76% | -63.72% | -277.78% | -16.61% | -22.24% | -44.71% | -40.32% | 58.42% | 32.14% |
FCF per Share | -1.83 | -1.73 | -2.71 | -10.22 | -11.14 | -13.13 | -17.43 | -21.48 | -8.47 | -9.38 |
FCF Conversion (FCF/Net Income) | 0.72x | 0.78x | 0.50x | 0.78x | 0.76x | 0.76x | 0.87x | 0.98x | 0.66x | 0.88x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MDGL Key Ratios
Madrigal Pharmaceuticals, Inc. (MDGL) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -28.49% | -9.95% | -18.79% | -61.61% | -110.92% | -150.12% | -123.98% | -80.35% | -42.49% | -50.15% |
Return on Invested Capital (ROIC) | -161.9% | -13.39% | -18.03% | -55.53% | -104.7% | -576.64% | -168.69% | -62.41% | -29.38% | -34.49% |
Gross Margin | - | - | - | - | - | - | - | 96.54% | 94.14% | 93.07% |
Net Margin | - | - | - | - | - | - | - | -258.64% | -30.08% | -27.32% |
Debt / Equity | - | - | 0.00x | 0.00x | 0.00x | 0.25x | 0.29x | 0.16x | 0.59x | 0.64x |
Interest Coverage | - | - | - | - | - | -73.51x | -28.39x | -30.76x | -11.92x | -25.80x |
FCF Conversion | 0.72x | 0.78x | 0.50x | 0.78x | 0.76x | 0.76x | 0.87x | 0.98x | 0.66x | 0.88x |
Revenue Growth | - | - | - | - | - | - | - | - | 432.05% | 256.82% |
Related:MDGL Dividend History·MDGL Revenue History·MDGL Price History·MDGL P/E History·MDGL Financial Ratios·MDGL Institutional Holders
MDGL SEC Filings & Documents
Madrigal Pharmaceuticals, Inc. (MDGL) SEC filings — annual & quarterly reports (10-K, 10-Q)
MDGL Frequently Asked Questions
Madrigal Pharmaceuticals, Inc. (MDGL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Madrigal Pharmaceuticals, Inc. (MDGL) reported $1.13B in revenue for fiscal year 2025. This represents a 86747% increase from $1.3M in 2003.
Madrigal Pharmaceuticals, Inc. (MDGL) grew revenue by 432.1% over the past year. This is strong growth.
Madrigal Pharmaceuticals, Inc. (MDGL) reported a net loss of $309.4M for fiscal year 2025.
Dividend & Returns
Madrigal Pharmaceuticals, Inc. (MDGL) has a return on equity (ROE) of -42.5%. Negative ROE indicates the company is unprofitable.
Madrigal Pharmaceuticals, Inc. (MDGL) had negative free cash flow of $272.4M in fiscal year 2025, likely due to heavy capital investments.